These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 29316337)

  • 21. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
    Francisco JA; Cerveny CG; Meyer DL; Mixan BJ; Klussman K; Chace DF; Rejniak SX; Gordon KA; DeBlanc R; Toki BE; Law CL; Doronina SO; Siegall CB; Senter PD; Wahl AF
    Blood; 2003 Aug; 102(4):1458-65. PubMed ID: 12714494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity.
    Jiang L; Yang M; Zhang X; Bao S; Ma L; Fan D; Zhou Y; Xiong D; Zhen Y
    J Drug Target; 2016; 24(1):47-57. PubMed ID: 26204323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
    Bhatt G; Maddocks K; Christian B
    Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
    Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
    BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Recombinant and Reconstituted Novel Albumin-Lidamycin Conjugate Shows Lasting Tumor Imaging and Intensively Enhanced Therapeutic Efficacy.
    Li L; Hu L; Zhao CY; Zhang SH; Wang R; Li Y; Shao RG; Zhen YS
    Bioconjug Chem; 2018 Sep; 29(9):3104-3112. PubMed ID: 30105903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers.
    Zhou DD; Zhai XT; Zhang LW; Xie ZH; Wang Y; Zhen YS; Gao RJ; Miao QF
    NPJ Precis Oncol; 2024 Apr; 8(1):94. PubMed ID: 38654141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy.
    Xu J; Liu XJ; Li L; Zhang SH; Li Y; Gao RJ; Zhen YS
    Oncotarget; 2015 Sep; 6(28):26322-34. PubMed ID: 26314845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity.
    Ru Q; Shang BY; Miao QF; Li L; Wu SY; Gao RJ; Zhen YS
    Eur J Pharm Sci; 2012 Nov; 47(4):781-9. PubMed ID: 22982402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of the antitumor activities of immunoconjugates composed of lidamycin and monoclonal antibody fab' fragment with different linkers].
    Feng Y; Shao RG; Dai Y; Li BW; He HW; Ren KH
    Yao Xue Xue Bao; 2010 May; 45(5):571-5. PubMed ID: 20931757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy.
    Zhang Q; Liu XJ; Hu L; Liao DS; Zheng YB; Zhen YS; Song X
    Int J Mol Med; 2012 Mar; 29(3):409-15. PubMed ID: 22108624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of the assembly efficiency for lidamycin chromophore bound to its apoprotein: a case study using orthogonal array.
    Zhong GS; Guo XF; Zhang SH; Zhen YS
    Biomed Environ Sci; 2011 Dec; 24(6):602-7. PubMed ID: 22365395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antitumor activities of various immunoconjugates composed of lidamycin and anti-type IV collagenase monoclonal antibody].
    Feng Y; Zhen YS; Dai Y; Shang BY; Zhang M; He HW; Li BW; Shao RG
    Yao Xue Xue Bao; 2007 Jul; 42(7):704-9. PubMed ID: 17882952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Construction of energized fusion protein consisting of epidermal growth factor receptor oligopeptide ligand and lidamycin and its antitumor activity].
    Guo XF; Zhong GS; Miao QF; Zhen YS
    Ai Zheng; 2009 Jun; 28(6):561-8. PubMed ID: 19635191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD30 as a therapeutic target for lymphoma.
    Schirrmann T; Steinwand M; Wezler X; Ten Haaf A; Tur MK; Barth S
    BioDrugs; 2014 Apr; 28(2):181-209. PubMed ID: 24043362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity.
    Miao QF; Liu XY; Shang BY; Ouyang ZG; Zhen YS
    Anticancer Drugs; 2007 Feb; 18(2):127-37. PubMed ID: 17159599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antitumor effect of lidamycin-containing monoclonal antibody immunoconjugate with downsized-molecule].
    Liu XY; Zhen YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec; 23(6):563-7. PubMed ID: 12901099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding capability of the enediyne-associated apoprotein to human tumors and constitution of a ligand oligopeptide-integrated protein.
    Cai L; Chen H; Miao Q; Wu S; Shang Y; Zhen Y
    J Biotechnol; 2009 Oct; 144(2):142-50. PubMed ID: 19737585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with K‑ras mutation.
    Sheng W; Geng J; Li L; Shang Y; Jiang M; Zhen Y
    Oncol Rep; 2020 Mar; 43(3):851-863. PubMed ID: 32020213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
    Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
    Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.